Peile Wang
Overview
Explore the profile of Peile Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
213
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang P, Liu S, He X, Miao W, Sun T, Yang J
J Antimicrob Chemother
. 2024 Jun;
79(8):1969-1973.
PMID: 38870067
Objectives: Central nervous system (CNS) infections caused by carbapenem-resistant Gram-negative bacteria (CR-GNB) present a major health and economic burden worldwide. This multicentre prospective study aimed to assess the feasibility and...
2.
Wang P, Liu S, Yang J
Clin Pharmacol Ther
. 2024 Mar;
116(2):363-371.
PMID: 38429919
Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis superinfection with cytokine storm is associated with increased mortality. This study aimed to establish a physiologically-based pharmacokinetic (PK) model to investigate the disease-drug-drug interactions...
3.
Wang P, Liu S, Sun T, Yang J
Int J Antimicrob Agents
. 2024 Jan;
63(3):107099.
PMID: 38280575
Background: Polymyxin B dosing in patients with sepsis is difficult because pathophysiological changes and supportive therapies alter drug pharmacokinetics (PK). This study aimed to investigate the impact of fluid management...
4.
Wang P, Liu S, Qi G, Xu M, Sun T, Yang J
Front Microbiol
. 2023 Sep;
14:1226981.
PMID: 37675417
Polymyxin B has been used as a last-line therapy for the treatment of carbapenem-resistant gram-negative bacterial infection. The pharmacokinetic/pharmacodynamic index (AUC/MIC) of polymyxin B has not been clinically evaluated, given...
5.
Wang P, Yin Z, Wang F, Yang J
J Pharm Biomed Anal
. 2023 Aug;
235:115683.
PMID: 37647792
Avatrombopag, eltrombopag, and hetrombopag are three oral thrombopoietin receptor agonists used to treat thrombocytopenia. To investigate the pharmacokinetic properties, a fast and robust UPLC-MS/MS method was developed and validated for...
6.
Wang P, Li H, Chen S, Xing H, Yang J, Zhang G, et al.
Clin Pharmacokinet
. 2023 May;
62(6):921-930.
PMID: 37142851
Background And Objective: Pirfenidone is an antifibrotic agent that has been proven to slow down the progression of idiopathic pulmonary fibrosis (IPF). This study aimed to characterize the population pharmacokinetics...
7.
Wang P, Xing H, Zhang X, Yang J
Clin Infect Dis
. 2023 Mar;
76(12):2209-2210.
PMID: 36942525
No abstract available.
8.
Liu P, Mai Y, Yuan W, Xie L, Ma W, Liu J, et al.
Infect Drug Resist
. 2022 Dec;
15:7307-7316.
PMID: 36536864
Purpose: Limited data are available on the characteristics, risk factors, and antimicrobial treatment of critically ill pediatric patients with carbapenem-resistant (CRE) infections. This study was to identify the risk factors...
9.
Li H, Yang J, Chen S, Wang P, Yu X, Zhou Q, et al.
Front Pharmacol
. 2022 Dec;
13:1055702.
PMID: 36523502
The high incidence and mortality of idiopathic pulmonary fibrosis (IPF) have led to the widespread use of antifibrotic drugs such as pirfenidone; however, the associated adverse reactions greatly vary among...
10.
Wang P, Liu D, Sun T, Zhang X, Yang J
Int J Antimicrob Agents
. 2022 Nov;
60(5-6):106693.
PMID: 36375775
There are limited data on the pharmacokinetics (PK) and pharmacodynamics (PD) of polymyxin B in the elderly population. The objective of this study was to develop a population PK model...